UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

February 28, 2009

Study Completion Date

July 31, 2010

Conditions
Multiple Myeloma
Interventions
PROCEDURE

High-Dose Density Therapy

Dexamethasone 40mg po 1-4, Thalidomide 200 mg po 1-6hrs then daily after transplant; Cisplatin\* 10 mg/m2 Continuous infusion 1-4;Adriamycin 10 mg/m2 Continuous infusion 1-4;Cyclophosphamide 400 mg/m2 Continuous infusion 1-4; Etoposide 40 mg/m2 Continuous infusion 1-4; Pegfilgrastim 6 mg subcutaneously 6 and 13; Darbepoetin 200μg subcutaneously Between -6 to-1 +12, \& every 2 weeks until HB \>12 gm/dl\*\*\*; Lovenox (or other LMWH) 40 mg subcutaneously Daily until Pltcount \<30,000/μl

Trial Locations (1)

72205

University of Arkansas for Medical Sciences, Little Rock

All Listed Sponsors
lead

University of Arkansas

OTHER

NCT00113932 - UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma | Biotech Hunter | Biotech Hunter